Literature DB >> 7356891

Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.

W J Leahey, J D Neill, M P Varma, R G Shanks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7356891      PMCID： PMC1429930          DOI： 10.1111/j.1365-2125.1980.tb04793.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  16 in total

1.  Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors:  C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

2.  Observations on the efficacy and pharmacokinetics of sotalol after oral administration.

Authors:  H C Brown; S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

Review 3.  The properties of beta-adrenoceptor antagonists.

Authors:  R G Shanks
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

4.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

6.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

7.  Propranolol given twice daily in hypertension.

Authors:  G Berglund; O Andersson; L Hansson; R Olander
Journal:  Acta Med Scand       Date:  1973-12

8.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

9.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

10.  Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding study.

Authors:  A P Douglas-Jones; N S Baber; A Lee
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953
View more
  23 in total

1.  Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?

Authors:  W M Blankesteijn; S J Graafsma; M P Hectors; E A Olde Riekerink; J F Rodrigues de Miranda; T Thien
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers.

Authors:  G Bano; R K Raina; U Zutshi; K L Bedi; R K Johri; S C Sharma
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

4.  A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

Authors:  R G Watson; W Bastain; K A Larkin; J R Hayes; J A McAinsh; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

5.  Pharmacology of propranolol in patients with cirrhosis and portal hypertension.

Authors:  M J Arthur; A R Tanner; C Patel; R Wright; A G Renwick; C F George
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

6.  A study of long acting propranolol in the early management of hyperthyroidism.

Authors:  G R Jones; J H Lazarus; D Wynford-Thomas
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

7.  Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Authors:  K Balnave; J D Neill; C J Russell; D W Harron; W J Leahey; R Wilson; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

8.  Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Authors:  D P Nicholls; D W Harron; J McAinsh; W M Castle; N P Barker; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 9.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

10.  Polymorphic metabolism of beta-adrenoceptor antagonists.

Authors:  J H Silas; M S Lennard; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.